These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 20436492)

  • 1. Oncolytic viruses: now interviewing for the all-star game.
    Vile R
    Mol Ther; 2010 May; 18(5):866-8. PubMed ID: 20436492
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of Group B Coxsackievirus as an Oncolytic Virus: Opportunities and Challenges.
    Liu H; Luo H
    Viruses; 2021 Jun; 13(6):. PubMed ID: 34198859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Introduction to Oncolytic Virotherapy.
    Engeland CE; Bell JC
    Methods Mol Biol; 2020; 2058():1-6. PubMed ID: 31486028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic virus therapy: A new era of cancer treatment at dawn.
    Fukuhara H; Ino Y; Todo T
    Cancer Sci; 2016 Oct; 107(10):1373-1379. PubMed ID: 27486853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosafety of non-human therapeutic viruses in clinical gene therapy.
    Hoeben RC; Louz D; Koppers-Lalic D
    Curr Gene Ther; 2013 Dec; 13(6):492-9. PubMed ID: 24397530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase 1 Trial of Oncolytic Adenovirus ICOVIR-5 Administered Intravenously to Cutaneous and Uveal Melanoma Patients.
    García M; Moreno R; Gil-Martin M; Cascallò M; de Olza MO; Cuadra C; Piulats JM; Navarro V; Domenech M; Alemany R; Salazar R
    Hum Gene Ther; 2019 Mar; 30(3):352-364. PubMed ID: 30234393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of talimogene laherparepvec (T-VEC) in the age of checkpoint inhibitors.
    Andtbacka RH
    Clin Adv Hematol Oncol; 2016 Aug; 14(8):576-9. PubMed ID: 27487099
    [No Abstract]   [Full Text] [Related]  

  • 8. Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.
    Zeng J; Li X; Sander M; Zhang H; Yan G; Lin Y
    Front Immunol; 2021; 12():721830. PubMed ID: 34675919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advance in herpes simplex viruses for cancer therapy.
    Liu S; Dai M; You L; Zhao Y
    Sci China Life Sci; 2013 Apr; 56(4):298-305. PubMed ID: 23564184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Metabolic Reprogramming to Improve the Efficacy of Oncolytic Virus Therapy.
    Kennedy BE; Sadek M; Gujar SA
    Mol Ther; 2020 Jun; 28(6):1417-1421. PubMed ID: 32243836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methods for Modification of Therapeutic Viruses.
    Hill CAP; Bau L; Carlisle R
    Methods Mol Biol; 2020; 2058():7-29. PubMed ID: 31486029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic interaction between oncolytic viruses augments tumor killing.
    Le Boeuf F; Diallo JS; McCart JA; Thorne S; Falls T; Stanford M; Kanji F; Auer R; Brown CW; Lichty BD; Parato K; Atkins H; Kirn D; Bell JC
    Mol Ther; 2010 May; 18(5):888-95. PubMed ID: 20234341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic Virotherapy Treatment of Breast Cancer: Barriers and Recent Advances.
    Kwan A; Winder N; Muthana M
    Viruses; 2021 Jun; 13(6):. PubMed ID: 34208264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial.
    Geletneky K; Hajda J; Angelova AL; Leuchs B; Capper D; Bartsch AJ; Neumann JO; Schöning T; Hüsing J; Beelte B; Kiprianova I; Roscher M; Bhat R; von Deimling A; Brück W; Just A; Frehtman V; Löbhard S; Terletskaia-Ladwig E; Fry J; Jochims K; Daniel V; Krebs O; Dahm M; Huber B; Unterberg A; Rommelaere J
    Mol Ther; 2017 Dec; 25(12):2620-2634. PubMed ID: 28967558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Photocontrollable mononegaviruses.
    Tahara M; Takishima Y; Miyamoto S; Nakatsu Y; Someya K; Sato M; Tani K; Takeda M
    Proc Natl Acad Sci U S A; 2019 Jun; 116(24):11587-11589. PubMed ID: 31138700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral cancer therapies: are they ready for combination with other immunotherapies?
    Boisgerault N; Grégoire M; Fonteneau JF
    Future Oncol; 2017 Aug; 13(18):1569-1571. PubMed ID: 28776392
    [No Abstract]   [Full Text] [Related]  

  • 17. Biodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and Tissues.
    Koski A; Bramante S; Kipar A; Oksanen M; Juhila J; Vassilev L; Joensuu T; Kanerva A; Hemminki A
    Mol Ther; 2015 Oct; 23(10):1641-52. PubMed ID: 26156245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor Targeting of Oncolytic Adenoviruses Using Bispecific Adapter Proteins.
    Niemann J; Kühnel F
    Methods Mol Biol; 2020; 2058():31-49. PubMed ID: 31486030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The viral approach to breast cancer immunotherapy.
    Arab A; Behravan N; Razazn A; Barati N; Mosaffa F; Nicastro J; Slavcev R; Behravan J
    J Cell Physiol; 2019 Feb; 234(2):1257-1267. PubMed ID: 30146692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy.
    Ricca JM; Oseledchyk A; Walther T; Liu C; Mangarin L; Merghoub T; Wolchok JD; Zamarin D
    Mol Ther; 2018 Apr; 26(4):1008-1019. PubMed ID: 29478729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.